29 results about "Transport protein" patented technology

This invention relates to a method for producing chondroitin with improved safety and extracellular secretion levels, belonging to the field of genetic engineering. Using the probiotic *Escherichia coli* Nissle 1917 as the host, this invention designs methods to increase chondroitin production by studying the chondroitin synthase KfoAC and the chondroitin-linking Kdo synthase. The relationship between chondroitin synthesis and secretion in *E. coli* was clarified, and the specificity of the chondroitin-linking Kdo was investigated, resulting in an extracellular chondroitin production of 0.32 g / L. Subsequently, the introduction of the protein KfoB from the chondroitin synthesis gene cluster increased the extracellular chondroitin production to 0.51 g / L. Further screening and optimization of the expression of transport proteins resulted in an extracellular chondroitin production of 0.73 g / L in shake flasks. Further optimization using a 7-L fermenter resulted in an extracellular chondroitin production of 5.9 g / L.

One aspect of the present invention relates to: a conjugate comprising a peptide of a novel sequence and glycyrrhizin; and a pharmaceutical composition for preventing or treating obesity, the composition comprising the conjugate. The conjugate and composition comprising same according to one aspect were found to inhibit hypertrophy of fat cells, increase the cell membrane expression level of ATP-binding cassette transporter A1 (ABCA1), and reduce the secretion of tumor necrosis factor-α (TNF-α). In addition, the conjugate and composition comprising same were found to remain in a greater amount in the blood and have better pharmacokinetic properties than glycyrrhizin used by itself, and thus can be used in the obesity prevention and / or treatment market / industry.

The application discloses a method for promoting transport and improving retinal synthesis, which is obtained by introducing an exogenous ABC transport protein Pdr5 into a host fungus and adding a copy of beta-carotene-15, 15'-monooxygenase BLH; wherein the host fungus is a genetically modified Pichia pastoris strain PP-BCCIV. The application further verifies the retinal production performance of the recombinant strain by screening different surfactants, and further improves the ability of Pichia pastoris to produce retinal. At the same time, all the retinal is extracted into the extracellular, and all the carotenes are left in the intracellular, so as to achieve the co-production of carotenes and retinal. The recombinant Pichia pastoris of the application has a simple construction method, can better promote the synthesis of retinal and other vitamin A, and can make the engineering strain utilize glucose and methanol to efficiently synthesize retinal through a 5 L fermentation tank, which is beneficial to industrial production.

The present invention relates to a novel PTS transporter subunit EIIC variant and a method of producing 5′-inosinic acid using the same. The PTS transporter subunit EIIC variant is obtained by substituting one or more amino acids in the amino acid sequence constituting PTS transporter subunit EIIC to change the activity of the protein, and a recombinant microorganism comprising the PTS transporter subunit EIIC variant is capable of efficiently producing 5′-inosinic acid.

This invention relates to the field of biosynthesis technology, and particularly to engineered yeast strains and their application in the total fermentation production of steviol glycosides. This invention utilizes site-directed mutagenesis to mutate wild-type kaurenoic acid 13-hydroxylase, obtaining the G481L / Q159L mutant. This mutant is then applied to the production of steviol or steviol glycosides, constructing a steviol or steviol glycoside synthesis pathway in the *Saccharomyces cerevisiae* host to achieve efficient production of steviol or steviol glycosides. Simultaneously, by enhancing the level of diterpene precursor synthesis genes in chassis cells (MVA pathway, acetyl-CoA, GGPP, transport proteins, UDPG pathway), the yield of steviol glycosides is further increased, reducing costs for industrial production.

Described herein are methods for disease or disorder associated with GABA transporter 1 (GAT-1) dysfunction. In one aspect described herein, the disease or disorder is associated with one or more solute carrier Family 6 Member 1 (SLC6A1) mutations, and 4-phenylbutyrate, or the pharmaceutically acceptable salt thereof, is administered at a dose of 75 mg / kg / day to 125 mg / kg / day. In another embodiment, the method comprises combined GAT-1 gene therapy combined with administration of 4-phenylbutyrate.

The application provides a genetically engineered bacterium for producing lactose-N-neotetraose, a construction method and application thereof. The genetically engineered bacterium satisfies the following conditions: (1) exogenous expression of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase; (2) overexpression of galactoside permease and UDP-galactose-4-epimerase; and (3) no expression or weakened expression of setA transporter protein. The applicant of the application finds through research that exogenous introduction of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase in the genetically engineered bacterium, enhancement of the expression amount of galactoside permease and UDP-galactose-4-epimerase in the genome, and reduction of the expression amount of setA transporter protein can effectively reduce the residual amount of LNT II in the LNnT synthesis pathway and improve the fermentation yield of LNnT.

The application discloses a ubiquitin transporter AcRAD23D1, a coding gene and application thereof, and belongs to the technical field of genetic engineering. The application clones an AcRAD23 family gene AcRAD23D1 from a kiwi fruit, and compares phenotypes and determines physiological parameters under transgenic and drought stress treatment, and identifies biological functions of the gene in positive regulation of drought resistance of the kiwi fruit in detail. The research result has important theoretical significance and practical application value for carrying out molecular directional breeding of the kiwi fruit. The overexpression transgenic kiwi fruit plant obtained by using the agrobacterium-mediated maceration method has significantly increased drought stress resistance, the transgenic kiwi fruit plant with silenced expression has significantly reduced drought stress resistance, and the application has important application value in molecular directional breeding of the kiwi fruit and reduction of cultivation environment limitation.

The invention represents new hybrid compounds of two natural products sclareol and doxorubicin in the form of their conjugates. These compounds are in the form of conjugates, where doxorubicin and sclareol are covalently linked by a linker in a 1:1 molar ratio. The hybrids have shown to possess anticancer properties and are effective in treating resistant cancer cells that have P-glycoprotein membrane transporter, responsible for resistance to doxorubicin. The hybrids have been tested on different types of cell lines, including human glioblastoma, non-small cell lung carcinoma, and colorectal carcinoma. Also, a method for their preparation and their use in medical products or pharmaceutical preparations has been determined. The results of the study include the cytotoxic activity of single, combined, and conjugated compounds in pairs of sensitive and resistant cancer cells, with and without P-glycoprotein expression. The selectivity towards cancer cells was determined by comparing with commercially available normal human lung fibroblast cells. The study also investigated the nanoparticle nature of hybrid compounds, their intracellular localization and toxicity in vivo.

This invention relates to the field of food processing technology and discloses a method for improving the stability and bioavailability of astaxanthin by combining piperine with a whey protein fibrillary-algin complex. The method specifically includes the following steps: S1. Preparation of whey protein fibrillary; S2. Loading piperine onto whey protein fibrillary; S3. Complexation of piperine-loaded whey protein fibrillary with sodium alginate; S4. Preparation of an astaxanthin-piperine co-encapsulated emulsion. This invention constructs a three-dimensional network resistant to pepsin hydrolysis through electrostatic complexation; enhances the effective concentration of piperine in the intestine through co-encapsulation, efficiently regulating the expression of P-gp efflux transport proteins and the transmembrane absorption of astaxanthin; and utilizes the functional property of piperine to inhibit the activity of P-gp efflux transport proteins to achieve efficient absorption of astaxanthin.

This invention proposes a six-dimensional strategy space modeling and collaborative optimization method for metabolic engineering, belonging to the field of biological technology. This method formally decomposes the metabolic engineering problem into six orthogonal transformation dimensions: heterologous biosynthetic pathway construction, competitive pathway reduction and flux redistribution, cofactor and precursor supply enhancement, product efflux and transport protein engineering, stress tolerance improvement, and process engineering optimization. A large language model is used to enumerate candidate strategies in each dimension. The synergistic and conflicting relationships between dimensions are evaluated through a genome-scale metabolic model (GEM) and enzyme constraint model. Combined with a hierarchical checkpoint human-computer interaction mechanism, the Pareto optimal strategy combination is output. Experimental results show that this method improves strategy design efficiency by 87.3% in the case of lactic acid production in Saccharomyces cerevisiae, and increases the strategy dimension coverage from an average of 2.7 dimensions in manual design to full coverage of 6 dimensions.

The positive allosteric modulator (PAM) of the EAAT2 / GLT-1 transporter for use in the treatment or prevention of pruritus is disclosed.

This invention discloses a sugar transporter gene. RkMAL1 Its nucleotide sequence is shown in SEQ ID NO:1, and the amino acid sequence encoded by this gene is shown in SEQ ID NO:2. This invention utilizes *Rhodotorula rubrum* (…). Rhodosporidium kratochvilovae Glycotransporter gene isolated from ) RkMAL1 uridine diphosphate glucose pyrophosphorylase RkUGPP After ligating the two components to a vector, they were transferred into *Rhodotorula rubrum* to achieve gene transfer. RkMAL1、 Gene RkMAL1+RkUGPP Overexpression of the gene significantly improves the synthesis efficiency of extracellular polysaccharides in recombinant strains. This invention provides a new method for producing extracellular polysaccharides, which is simple, easy to operate, and offers good application prospects for the large-scale production of extracellular polysaccharides.

This invention discloses an aromatic compound transporter protein mutant and its applications, belonging to the field of bioengineering technology. The mutant is based on *Pseudomonas putida* (…). Pseudomonas putida The outer membrane transport protein derived from [a specific source] is obtained by site-directed substitution of key residues in its gating loop. Specifically, this includes replacing phenylalanine at position 120 with glycine, leucine at position 121 with glycine, and glutamine at position 122 with glycine, or one or more combinations thereof. Preferred mutants include single mutant F120G, double mutant F120G / L121G, or triple mutant F120G / L121G / Q122G, and conserved substitution derivatization can also be performed based on these mutants. These mutants can be used for the efficient microbial production and cell tolerance regulation of aromatic compounds, based on the physicochemical properties of the target product, and have significant application value in green biomanufacturing, fermentation engineering, and bioremediation.

The invention relates to a method for determining an anti-blood group antibody and / or an anti-CD38 antibody in a biological sample, comprising the following steps: a) providing a biological sample comprising erythrocytes expressing a transport protein (CD38); b) providing a polypeptide specific for CD38 and comprising an amino acid sequence; c) contacting and incubating the biological sample with the polypeptide; and d) determining an anti-blood group antibody and / or an anti-CD38 antibody in the biological sample. The invention further relates to a device and a kit for determining an anti-blood group antibody and / or an anti-CD38 antibody in a biological sample, as well as an expression system for producing a polypeptide according to the invention.

This invention discloses a PAEs transporter system from Rhodococcus and its application in enhancing phthalate degradation. The system comprises four transporters: 0620 (amino acid sequence as shown in SEQ ID NO:1), 3572 (amino acid sequence as shown in SEQ ID NO:2), 4497 ​​(amino acid sequence as shown in SEQ ID NO:3), and 5299 (amino acid sequence as shown in SEQ ID NO:4). These transporters work synergistically and exhibit differentiated PAEs substrate preferences. The transporters provided by this invention have a broad substrate spectrum and high efficiency, offering core components and application strategies for constructing highly efficient PAEs bioremediation engineered bacteria.

This invention provides an application of *Lactobacillus plantarum* peptidoglycan in the preparation of uric acid-lowering products, relating to the biomedical field. This *Lactobacillus plantarum* peptidoglycan is derived from *Lactobacillus plantarum* (accession number CGMCC No. 25306). Lactobacillus plantarum Extracted from YC, its chemical structure is A1γ. This plant lactobacillus peptidoglycan can regulate uric acid homeostasis through multiple synergistic mechanisms: inhibiting hepatic XOD activity to reduce uric acid production; bidirectionally regulating renal and intestinal uric acid transport proteins (upregulating ABCG2 / OAT1, downregulating URAT1 / GLUT9) to promote excretion; and exerting systemic anti-inflammatory and hepatoprotective effects. This plant lactobacillus peptidoglycan has a significant uric acid-lowering effect without hepatotoxicity or nephrotoxicity, and its safety is superior to allopurinol. This invention provides a novel core material basis and solution for developing multi-pathway, highly safe uric acid-lowering products.

According to one aspect of the present invention, this method for detecting Fusobacterium nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific to a citrate lyase beta subunit gene of Fusobacterium nucleatum. According to said method, F. nucleatum can be specifically detected. According to another aspect of the present invention, this method for detecting Fusobacterium nucleatum nucleatum in a sample involves a step for subjecting a DNA derived from a sample to nucleic acid amplification reaction using a primer set specific to a dicarboxylate / amino acid: cation cotransporter gene of Fusobacterium nucleatum nucleatum. According to said method, F. nucleatum nucleatum can be specifically detected.

The application relates to the field of biological medicine, and particularly relates to a high-stability membrane protein and a preparation method thereof. The preparation method comprises the following steps: firstly, preparing a membrane vesicle suspension by using cells overexpressing a target membrane protein; then, adding a membrane structure regulator and a temperature-sensitive biomimetic copolymer in sequence, and incubating by increasing temperature to form a membrane disc suspension; subsequently, adding a mild detergent, and obtaining an extraction liquid by stirring and standing after keeping warm, cooling and standing, and ultracentrifugation; then, obtaining a membrane protein purified liquid by ultrafiltration concentration and salt gradient washing and filtering; finally, adding a freeze-drying protective agent, and preparing the high-stability membrane protein by pre-freezing and vacuum freeze-drying. The application utilizes the synergistic effect of the membrane structure regulator and the temperature-sensitive biomimetic copolymer, and combines the mild detergent extraction and the composite freeze-drying protective agent, so that the extraction efficiency, purity, biological activity and long-term storage stability of the membrane protein are significantly improved. The method is suitable for the preparation of various membrane proteins such as G protein-coupled receptors, ion channels and transport proteins.

This invention relates to albumin-bound BODIPY derivatives, their preparation, and applications, belonging to the field of pharmaceutical technology. The albumin-bound BODIPY derivative of this invention couples BODIPY with the albumin-free non-covalent binder 4-(p-iodophenyl)butyric acid (IP), and can be further coupled with a boron thiol compound (BSH). 4-(p-iodophenyl)butyric acid has excellent albumin-binding ability; by utilizing the EPR effect of albumin, tumor-targeted delivery of boron-containing modules (BODIPY or BSH) can be achieved, overcoming the dependence of traditional boron drugs 4-dihydroxyboron-L-phenylalanine (BPA) on the LAT1 transporter protein, and exhibiting a certain degree of broad-spectrum targeting. Simultaneously, the fluorine-18 (…) introduced into the BODIPY structure… 18 The F) atom allows for real-time monitoring of the distribution of boron-containing drugs in vivo via PET-CT, enabling integrated diagnosis and treatment of tumors. This conjugate exhibits high safety and low toxicity, high in vitro cellular uptake, and in vivo animal distribution experiments confirming its excellent tumor targeting properties. This invention can serve as a broad-spectrum targeted boron-containing drug in integrated BNCT diagnosis and treatment.

The application discloses application of VvNRT1.1 and VvCNGC15 proteins in improving nitrogen utilization rate of grape, and belongs to the technical field of plant genetic engineering and molecular breeding. The application proves that the VvNRT1.1 and VvCNGC15 proteins directly physically interact, and overexpression of the VvNRT1.1 or VvCNGC15 can improve the absorption and assimilation efficiency of nitrate nitrogen of grape. Therefore, the VvNRT1.1 and VvCNGC15 can be used as key molecular targets for improving nitrogen utilization rate, and have potential application value.

The invention relates to an application of a transporter and a gene thereof in improving tolerance of filamentous fungi to ionic liquid, and belongs to the technical field of genes. The invention aims to solve the problems that the stability of filamentous fungi in ionic liquid is poor at present, so that a fungus and ionic liquid synergistic technology is difficult to effectively apply and the like. The invention provides a transporter for improving tolerance of fungi to ionic liquid and a gene of the transporter. The nucleotide sequence of the transporter gene is shown as SEQ ID NO.1; the amino acid sequence of the transporter is as shown in SEQ ID NO. 2. After gene overexpression of the transporter provided by the invention, tolerance of filamentous fungus aspergillus terreus to ionic liquid is improved, including improvement of growth ability of a strain in the ionic liquid and improvement of activity of cellulase and hemicellulase of the strain in the ionic liquid.

The application discloses a method for analyzing gibberellin GA4 high-yield mechanism of Gibberella fujikuroi based on comparative transcriptomics, and belongs to the field of industrial microorganisms. The method constructs a correlation model of "specific genotype strain-standardized fermentation-time sequence transcriptome analysis", and systematically analyzes the dynamic regulation network of product synthesis through high-fidelity sampling at multiple time points, high-throughput sequencing, differential expression analysis, time sequence clustering and weighted gene co-expression network analysis. The core lies in converging massive data into a short list of key target genes stably associated with high-yield traits, including rate-limiting enzymes, transport proteins and regulatory factors, so as to guide the rational design of metabolic engineering and strain improvement. The application forms a standardized and iterative systematic solution, and provides clear molecular targets and efficient methodological tools for breaking through the yield bottleneck of natural product fermentation.

The invention relates to methods for determining an anti-blood group antibody and / or an anti-CD38 antibody in a biological sample, comprising the following steps: a) providing a biological sample comprising erythrocytes, wherein the erythrocytes express a transport protein (CD38); and b) providing a polypeptide which is specific to CD38 and comprises an amino acid sequence; and c) contacting and incubating the biological sample with the polypeptide; and d) determining an anti-blood group antibody and / or an anti-CD38 antibody in the biological sample. The invention further relates to a device and a kit for determining an anti-blood group antibody and / or an anti-CD38 antibody in a biological sample, and to an expression system for producing a polypeptide according to the invention.

This invention relates to the field of agricultural biotechnology, specifically to a method and strain for constructing an engineered strain of *Hookworm Copper-Gropping Bacteria* capable of producing methylmalic acid using both organic and inorganic carbon sources. This application involves knocking out the restriction endonuclease encoding gene of the type I restriction modification system in the genome of wild-type *Hookworm Copper-Gropping Bacteria* H16. 、 Promoters adapted for methylmalate synthase expression in *Hypoxonometra* were screened, and methylmalate synthases with high catalytic activity in *Hypoxonometra* were obtained, capable of effectively catalyzing methylmalate synthesis in *Hypoxonometra*. A methylmalate transporter protein that promotes methylmalate excretion was also screened, as well as a gene encoding the *Hypoxonometra* endogenous pyruvate dehydrogenase complex subunit that promotes methylmalate synthesis when sodium gluconate is used as a carbon source.

This method for measuring transporter activity comprises: exposing a membrane vesicle having a vacuolar ATPase and a vesicular nucleotide transporter to an anion which is labeled with a radionuclide and is different from adenosine triphosphate, in a reaction solution containing adenosine triphosphate and magnesium ions; and measuring the transport activity of the anion into the membrane vesicle on the basis of the radiation of the radionuclide.

This invention relates to a method and its application for enhancing the synthesis of serotonin and melatonin in *Escherichia coli*, belonging to the field of genetic engineering technology. This invention achieves the following results through the heterologous expression of high-yield serotonin and melatonin compounds Tph, Tdc, SNAT, and COMT in *Escherichia coli*, and through enzyme engineering, metabolic engineering, transport protein engineering, and reaction condition optimization: the optimized yield of serotonin synthesized from tryptophan reaches 1.92 g / L; the yield of melatonin synthesized from tryptophan reaches 3.40 g / L.

The application discloses application of a piRNA-145836 preparation in preparation of a medicine for preventing and treating type 2 diabetes induced by high homocysteine, and belongs to the technical field of biological medicine and molecular biology. The nucleotide sequence of the piRNA-145836 is shown as SEQ ID No. 1. The piRNA-145836 can play a key role in type 2 diabetes induced by high homocysteine, and can regulate a mechanism, promote recovery of pancreatic function, restore insulin secretion capacity, reduce abnormal activation of copper death-related proteins, reduce accumulation of copper ions in islet beta cells, and improve sugar metabolism disorder induced by high homocysteine. The application solves the technical problems of lack of cognition of the role of piRNA in copper ion homeostasis and beta cell fate determination, ambiguity of the role target of resveratrol, and unknown expression regulation mechanism of key copper transport proteins in a high homocysteine environment in the prior art.

This invention discloses a Torreya grandis MATE transporter protein TgMATE72, its encoding gene, and its applications. The amino acid sequence of the transporter protein TgMATE72 is shown in SEQ ID NO.2, and the nucleotide sequence of the encoding gene is shown in SEQ ID NO.1. This invention also provides the application of the transporter protein TgMATE72 and its encoding gene in regulating the transport of proanthocyanidin precursors and increasing proanthocyanidin content in plants. Based on the combined analysis of transcriptome data from Torreya grandis seed development and the content of proanthocyanidins and their monomers, this invention screened and obtained TgMATE72, and its expression level is positively correlated with the accumulation of catechin monomers. Sequence alignment and phylogenetic analysis show that the transporter protein TgMATE72 belongs to the plant MATE transporter protein family. Heterologous expression and transport activity detection results in Xenopus laevis oocytes show that TgMATE72 can mediate the transport of catechin monomers. This invention provides gene resources and application methods for improving proanthocyanidin-related traits in plants, and can be used for molecular breeding and quality improvement of Torreya grandis and other plants.